CN1846694A - Application of substituted aryl biguanide compounds and pharmaceutical compositions containing them in the preparation of anticancer drugs - Google Patents
Application of substituted aryl biguanide compounds and pharmaceutical compositions containing them in the preparation of anticancer drugs Download PDFInfo
- Publication number
- CN1846694A CN1846694A CN 200510013308 CN200510013308A CN1846694A CN 1846694 A CN1846694 A CN 1846694A CN 200510013308 CN200510013308 CN 200510013308 CN 200510013308 A CN200510013308 A CN 200510013308A CN 1846694 A CN1846694 A CN 1846694A
- Authority
- CN
- China
- Prior art keywords
- biguanide
- hydrochloride
- cell
- phenyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 substituted aryl biguanide compounds Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 title claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 title claims description 3
- 229940123208 Biguanide Drugs 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 27
- 201000011510 cancer Diseases 0.000 claims abstract description 17
- 206010027476 Metastases Diseases 0.000 claims abstract description 12
- 201000001441 melanoma Diseases 0.000 claims abstract description 11
- 206010064390 Tumour invasion Diseases 0.000 claims abstract description 10
- 230000009400 cancer invasion Effects 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 8
- 206010018338 Glioma Diseases 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 8
- 230000009401 metastasis Effects 0.000 claims abstract description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 7
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 7
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 2
- 201000005202 lung cancer Diseases 0.000 claims abstract 2
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 34
- FKPUYTAEIPNGRM-UHFFFAOYSA-N 1-(diaminomethylidene)guanidine;hydron;chloride Chemical compound [Cl-].N\C([NH3+])=N/C(N)=N FKPUYTAEIPNGRM-UHFFFAOYSA-N 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 230000005747 tumor angiogenesis Effects 0.000 claims description 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims 3
- 125000002071 phenylalkoxy group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- KRWFGEYBAWMPBG-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-ethoxyphenyl)guanidine Chemical compound CCOC1=CC=CC=C1N=C(N)N=C(N)N KRWFGEYBAWMPBG-UHFFFAOYSA-N 0.000 claims 1
- WNHFACPBCAFOGU-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-methylsulfanylphenyl)guanidine;hydrochloride Chemical compound Cl.CSC1=CC=CC=C1N=C(N)N=C(N)N WNHFACPBCAFOGU-UHFFFAOYSA-N 0.000 claims 1
- WEOIHIYCKWSSBW-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(3-nitrophenyl)guanidine Chemical compound NC(N)=NC(N)=NC1=CC=CC([N+]([O-])=O)=C1 WEOIHIYCKWSSBW-UHFFFAOYSA-N 0.000 claims 1
- HBYJTLZNKNUTCP-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(4-fluorophenyl)guanidine;hydrochloride Chemical compound [Cl-].N\C([NH3+])=N/C(N)=NC1=CC=C(F)C=C1 HBYJTLZNKNUTCP-UHFFFAOYSA-N 0.000 claims 1
- QQSNDWJEVQKWPW-UHFFFAOYSA-N 1-(diaminomethylidene)-2-[4-(trifluoromethylsulfanyl)phenyl]guanidine;hydrochloride Chemical compound Cl.NC(N)=NC(N)=NC1=CC=C(SC(F)(F)F)C=C1 QQSNDWJEVQKWPW-UHFFFAOYSA-N 0.000 claims 1
- SJPLIZPAHCNLFD-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-1-(diaminomethylidene)guanidine Chemical compound CC1=CC=C(Cl)C=C1N=C(N)N=C(N)N SJPLIZPAHCNLFD-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- IGFTZEOFHWPCDL-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]imidodicarbonimidic diamide Chemical compound NC(=N)NC(=N)NC1=CC(C(F)(F)F)=CC=C1Cl IGFTZEOFHWPCDL-UHFFFAOYSA-N 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 22
- 230000033115 angiogenesis Effects 0.000 abstract description 13
- 238000001727 in vivo Methods 0.000 abstract description 7
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000012404 In vitro experiment Methods 0.000 abstract 1
- 230000009876 antimalignant effect Effects 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 56
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 20
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 8
- 238000011580 nude mouse model Methods 0.000 description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 201000001514 prostate carcinoma Diseases 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 210000003725 endotheliocyte Anatomy 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010031318 Vitronectin Proteins 0.000 description 4
- 102100035140 Vitronectin Human genes 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000025164 anoikis Effects 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004987 nonapoptotic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100022337 Integrin alpha-V Human genes 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229940122081 5 Hydroxytryptamine receptor agonist Drugs 0.000 description 1
- 102100024954 5-hydroxytryptamine receptor 3A Human genes 0.000 description 1
- 101710138027 5-hydroxytryptamine receptor 3A Proteins 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010040765 Integrin alphaV Proteins 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000035307 Vitreous adhesions Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical group 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及取代芳香基双胍类化合物及含它们的药物组合物在制备抗恶性肿瘤药物方面的应用。本发明的取代芳香基双胍类化合物经体内外实验，显示出明显的抑制肿瘤细胞的作用，同时具有高效、低毒的特点，因此作为药物化合物有望应用在抑制肿瘤侵袭转移和血管新生以及治疗整合素αvβ3高表达的人黑色素瘤、神经胶质瘤、肺癌、胃癌、前列腺癌、卵巢癌等多种恶性肿瘤方面。The invention relates to the application of substituted aryl biguanide compounds and pharmaceutical compositions containing them in the preparation of anti-malignant tumor drugs. The substituted aryl biguanide compound of the present invention has shown obvious tumor cell inhibitory effect through in vivo and in vitro experiments, and has the characteristics of high efficiency and low toxicity. Therefore, it is expected to be used as a pharmaceutical compound in inhibiting tumor invasion and metastasis, angiogenesis and therapeutic integration. Human melanoma, glioma, lung cancer, gastric cancer, prostate cancer, ovarian cancer and other malignant tumors with high expression of αvβ3.
Description
Technical field
The present invention relates to use the method for a series of substituted aromatic base biguanide compound treatment malignant tumor, a kind of application of pharmaceutical composition aspect multiple malignant tumor such as the Humanmachine tumour that suppresses tumor invasion transfer and angiogenesis and treatment integrin alpha v beta 3 high expressed, glioma, pulmonary carcinoma, gastric cancer, carcinoma of prostate, ovarian cancer that has the substituted aromatic base biguanide compound of anti-tumor activity and contain this compounds for the treatment of effective dose of saying so more specifically.
Background technology
Malignant tumor is a big class disease of serious threat human health, and its paraplasm is that unusual information is controlled in the cell, and is closely related with the Showed Very Brisk and the inactivation of corresponding gene in the tumor cell.Traditional cancer therapy drug mainly is a cell toxicity medicament, difference between the kinetics of their dependence tumor cells and normal cell growth, reparation, death is come killing tumor cell, therefore this class medicine inevitably can influence normal cell, it is narrow to treat window clinically, has also limited the enforcement of multiple medicines combined chemotherapy.There are many cancer therapy drugs at molecular target to occur in recent years, this class medicine with strong points, effect is remarkable, just looks like that to hit target the same, therefore is called as " target agent ".Paul Ehrlich has just proposed the notion of targeted therapy (targeting therapy) before 100 years, the going deep into along with development of molecular biology and people to the research of tumor mechanism, target agent at specific carcinogenic mechanism has obtained very fast development in recent years, the carcinogenic cause of disease of these medicine direct aggressions, selectivity is strong, clinical trial result is remarkable, and side effect is light, and multiple medicines is united the effect that use can strengthen traditional chemotherapeutics often.
Integrating plain (integrin) is the important cell surface molecule of a class, belongs to cell surface receptor family, is made up of α and two kinds of subunits of β.It is relevant to integrate the plain adhesion and the generation of numerous disease by mediated cell and cell, cell and extracellular matrix, and wherein integrin alpha v beta 3 (CD51/CD61) plays an important role in processes such as neoplasm metastasis, angiogenesis, inflammation, neointimal hyperplasia.Why integrin alpha v beta 3 becomes an effectively treatment target spot, be because its wide expression in normal cell not, just high expressed in the smooth muscle cell of new vessels and endotheliocyte and the especially invasive tumor cell of multiple malignant tumor comprises Humanmachine tumour, glioma, pulmonary carcinoma, gastric cancer, carcinoma of prostate, ovarian cancer etc.
A lot of tumor patients are unavoidable after treatment recurrence to be occurred and extensively shifts three adhesions that committed step is tumor cell and basement membrane that tumor invasion shifts, degradation of extracellular matrix, and cell migration.Special adhesion process of many stages is arranged in this process, the expression of some of them cell adhesion molecule, especially the metastatic potential of integrin alpha v beta 3 and tumor cell is closely related, it by promoting tumor transfer and invade the malignant phenotype that the profit ability makes tumor and increase, can be used as a sign of the tumor cell of many invasion and attack.For example in one of the strongest tumor of transitivity human melanoma, tumor cell to the invasive ability of many tissues and extracellular matrix to a great extent owing to the receptor-mediated effect of surface adhesion, wherein, integrin alpha v beta 3 has been brought into play important function in melanomatous transfer and propagation, it can by with the adhesion of its part, the mediation melanoma cell shifts to many tissues.It is and for example local that to invade profit be one of characteristics of glioblastoma, this is also closely related with the unconventionality expression of integrin alpha v beta 3, invading the glioma cell of profit can send out along some structure that contains stromatin (as the medial surface of blood vessel wall basement membrane) by the effect of α v β 3.
The formation of new vessels can impel tumor to increase rapidly, and increases the risk of neoplasm metastasis.Integrin alpha v beta 3 is confirmed to be a sign of angiogenesis, it is seldom expressed in the normal blood vessels of resting stage, but under tumor or certain growth factor-induced, integrin alpha v beta 3 obviously increases in the expression of new vessels endotheliocyte, can be by promoting the new vessels endothelial cell migration, suppress its apoptosis, and promote the little vessel growth of former and metastatic tumour and increase it to invade the profit ability, its malignant phenotype is increased.Can regulate the angiogenesis of tumor inducing to the inhibition of integrin alpha v beta 3, increase the apoptosis of the little vascular endothelial cell relevant with tumor, angiogenesis reduces, and can also regulate the activity of osteoclast, and the hypercalcemia that occurs together of control malignant tumor.
At present the inhibitor at integrin alpha v beta 3 mainly contains 37 kinds, wherein has two kinds carrying out II phase clinical experiment, is a kind ofly carrying out I phase clinical experiment.These inhibitor mainly are divided three classes: the first kind is a monoclonal antibody, Humanized monoclonal antibodies Vitaxin and its second filial generation antibody Vitaxin II comprising integrin alpha v beta 3, in its II phase clinical experiment, be used for studying to the melanoma of carcinoma of prostate, transfer and the colon cancer in late period and leiomyosarcoma patient's therapeutic activity.Also has Johnson ﹠amp in addition; The humanized antibody CTNO-95 of Johnson company, clinical preceding experiment shows that it can suppress the growth of nude mice human melanin transplanted tumor, is carrying out multicenter I phase clinical experiment at present; Second class is polypeptide and polypeptide analogies, comprise by the little molecule cyclic peptide analog EMD121974 of Merck company exploitation, can the antagonism integrin alpha v beta 3 vascular endothelial cell of mediation and the interaction of extracellular matrix, carry out the II clinical trial phase, be used for the treatment of the research of tumor of head and neck, pulmonary carcinoma, cancer of pancreas, breast carcinoma, melanoma, tumor of kidney and colon cancer; The 3rd class is non-peptide type small molecular inhibitor, and what studying at present mainly is benzodiazepines, comprises SB223245 etc., can significantly suppress the cell adhesion of integrin alpha v beta 3 mediation.The peptide class is subject to the degraded of enzyme in vivo, and the half-life is short, develops the medicine of corresponding non-peptide type small molecular inhibitor, long action time in vivo not only, and can orally use, be one of development in future direction.Reported the crystal structure of integrin alpha v beta 3 extracellular region and ligand complex in April, 2002 on the Science, this research just is being based on this achievement in research, the means of utilizing the computer high flux screening to combine with Chemoinformatics, receptor binding site to integrin alpha v beta 3 carries out database search, screening is sought the new drug of diseases such as transfer of control tumor invasion and angiogenesis at the micromolecular inhibitor of integrin alpha v beta 3.
We find first, substituted aromatic base biguanide compound of the present invention is aspect the medicine of multiple malignant tumor such as the Humanmachine tumour for preparing inhibition tumor invasion transfer and angiogenesis and treatment integrin alpha v beta 3 high expressed, ovarian cancer, glioma, pulmonary carcinoma, gastric cancer, carcinoma of prostate, demonstrate effective pharmacologically active, open up a new way for seeking new effective antitumour medicine.
Before the present invention, the substituted aromatic base biguanide compound is once by as 5-hydroxytryptamine receptor 3 agonist, can further stop the conduction of postsynaptic noxious stimulus by promoting the release of γ-An Jidingsuan, once be used for the research etc. that non-opium does not have the addiction analgesic.Brain Res.2003 Jul 18; 978 (1-2): 250-5; Pain.1997Jul; 71 (3): 237-47; Gen Pharmacol.1991; 22 (2): reported this pharmacological action of 5-hydroxytryptamine receptor agonist among the 247-51.But it is at anti-tumor aspect, and the application that especially suppresses tumor invasion transfer and angiogenesis aspect was not studied always.
Substituted aryl biguanide compound of the present invention synthetic referring to Cohn, J.Prakt.Chem.[2] 84,396 Jacobs, Jolles, Brit, pat.587,907 (1947 to ICI).Chemical compound of the present invention can have been bought from the market or make by the method for reporting in above-mentioned method or other document.
Summary of the invention
First purpose of the present invention has been to disclose the application of substituted aromatic base biguanide compound at the preparation medicine for resisting malignant tumors.
The present invention further discloses the application of substituted aromatic base biguanide compound aspect preparation inhibition tumor invasion diversion medicaments.
The present invention further discloses the application of substituted aromatic base biguanide compound aspect preparation inhibition neonate tumour blood vessel medicine.
The present invention further discloses the application of substituted aromatic base biguanide compound aspect the medicine of malignant tumor such as preparation treatment Humanmachine tumour, ovarian cancer, pulmonary carcinoma, gastric cancer, carcinoma of prostate, glioma again.
Second purpose of the present invention has been to provide the pharmaceutical composition that is used for the treatment of malignant tumor, and it comprises as the chemical compound of the claim 1 of active component or 5 or 6 and one or more pharmaceutically acceptable carriers, excipient or diluent.
The invention provides as shown in the formula the application of the substituted aromatic base biguanide compound of I at the preparation medicine for resisting malignant tumors with anti-tumor activity:
Wherein:
R ' is phenyl, benzene alkyl, benzene thiazolinyl, benzene alkoxyl, phenoxy group, the thiophenyl of H, phenyl, replacement;
R is R
1The phenyl, benzene alkyl, benzene thiazolinyl, benzene alkoxyl, phenoxy group, the thiophenyl that replace;
R
1For containing C
1-C
6Straight or branched alkyl, C
1-C
4Perfluoroalkyl, C
1-C
4Alkanoyl, C
1-C
4Ester group, aryl, halogen, NO
2, NH
2,-H ,-OR
2,-SR
2
R
2Be C
1-C
6Straight or branched alkyl, C
1-C
4Perfluoroalkyl, C
1-C
4Alkanoyl;
R or R ' can be single or multiple substituent groups, and are in para-position or an ortho position or a position on the aromatic ring respectively.
The present invention includes the pharmaceutically acceptable mineral acid and the acylate of I compounds, comprise hydrochlorate, phosphate, sulfate, acetate, maleate, citrate, benzene sulfonate, toluenesulfonate, fumarate, tartrate etc.
The present invention seeks the antitumor drug that suppresses tumor invasion transfer and angiogenesis with the means of computer ancillary drug design, we are to the three-dimensional structure database that contains 90,000 micromolecular compounds screening of giving a mark, (energy value is low more finally to obtain 1000 forward chemical compounds of score, score is forward more), wherein the substituted aromatic base biguanide compound has all entered the scope of preceding 1000 chemical compounds, and representative chemical compound has:
| Chemical compound | Energy value |
| N-benzyl biguanide p-methyl benzenesulfonic acid salt (1) | -46.44 |
| The N-{4-[(trifluoromethyl) sulfo-] phenyl } biguanide hydrochloride (2) | -54.06 |
| N-(3-chloro-phenoxy group) biguanide (3) | -34.19 |
| 3-biguanide-ethyl benzoate hydrochlorate (4) | -33.89 |
| N-(2-ethylphenyl) biguanide hydrochloride (5) | -36.9 |
| N-benzyl-N-phenyl biguanide p-methyl benzenesulfonic acid salt (6) | -42.76 |
| N-(3, the 4-Dichlorobenzene base) biguanide (7) | -47.07 |
| The N-{3-[(methyl) sulfo-] phenyl } biguanide hydrochloride (8) | -43.35 |
| The N-{2-[(methyl) sulfo-] phenyl } biguanide hydrochloride (9) | -45.48 |
| N-(2-chloro-5-trifluoromethyl) biguanide (10) | -47.24 |
| N-(2-ethoxyl phenenyl) biguanide (11) | -46.96 |
| N-(5-chloro-2-aminomethyl phenyl) biguanide (12) | -38.38 |
| The N-{4-[(difluoromethyl) sulfo-] phenyl } biguanide hydrochloride (13) | -46.77 |
| N-(3-chloro-4-ethoxy benzyl) biguanide hydrochloride (14) | -48.86 |
| N-(3-chloro-4-methoxy-benzyl) biguanide hydrochloride (15) | -50.16 |
| N-(4-chloro-2-aminomethyl phenyl) biguanide hydrochloride (16) | -42.43 |
| N-(3-chloro-4-fluorophenyl) biguanide hydrochloride (17) | -44.85 |
| N-(4-Trifluoromethoxyphen-l) biguanide hydrochloride (18) | -38.95 |
| N-(3-nitrobenzophenone) biguanide (19) | -46.02 |
| N-(3-chloro-4-fluorobenzene methoxyl group) biguanide (20) | -39.89 |
| N-(2, the 4-Dichlorobenzene base) biguanide hydrochloride (21) | -47.70 |
| N-(2, the 3-Dichlorobenzene base) biguanide hydrochloride (22) | -46.73 |
| N-(4-fluorophenyl) biguanide hydrochloride (23) | -48.30 |
We have further carried out Determination of biological activity to these substituted aromatic base biguanide compounds, find that they all have in various degree inhibitory action to tumor cell adhesion, Invasion and Metastasis and neonate tumour blood vessel.
Description of drawings:
Fig. 1 is a substituted aromatic base biguanide compound structural formula;
Fig. 2 suppresses lab diagram for tumor cell adhesion;
Fig. 3 is cell injury healing lab diagram;
Fig. 4 forms lab diagram for the vascular endothelial cell tube chamber; Wherein, Fig. 4 A is for being the inductive blank group of the no factor, and Fig. 4 B is the positive controls of the bFGF of adding 100ng/ml, and Fig. 4 C is for adding the processed group of 100ng/mlbFGF and 10 μ g/mlN-(3, the 4-Dichlorobenzene base) biguanide simultaneously.
Fig. 5 is the apoptosis lab diagram, wherein, adds N-(3, the 4-Dichlorobenzene base) biguanide of 0,5 μ g/ml and 10 μ g/ml among Fig. 5 A, Fig. 5 B, Fig. 5 C respectively.
At this,, provide the pharmacological experimental data of exemplary embodiments N-of the present invention (3, the 4-Dichlorobenzene base) biguanide below in order to show the practicality of target compound.
The experiment of pharmacological evaluation one tumor cell adhesion
Principle:
Corresponding part adheres to tumor cell in film surface receptor such as element and the extracellular matrix by integrating, and adhesion is the initiating step that tumor cell invasion shifts, and helps normal structures such as tumor cell infringement basement membrane.This method is used to measure the influence of chemical compound to tumor cell and basement membrane components adhesive capacity.Select the human melanoma cell system of integrin alpha v beta 3 high expressed to be as subject cell, the ligands specific albumen vitronectin bag of selecting integrin alpha v beta 3 is by 96 orifice plates, add test-compound when adding cell, after hatching after a while, rinse out not adherent cell, adhere to the light absorption value that the cell quantity on the plate measures with the crystal violet method and reflect.
Experimental technique:
Experiment is divided into two groups: N-(3, the 4-Dichlorobenzene base) biguanide group and negative control chemical compound group.Establish six dosage of 50,25,12.5,6.25,3.13,1.56 μ g/ml altogether.Other establishes and adds isopyknic solvent in the blank, adheres to contrast, cell adhesion suppression ratio and half amount of suppression (IC50) in the experiment with computing group as cell 100%.
Add the every hole 100 μ l of 5 μ g/ml vitreous adhesion albumen (vitronectin) in (1) 96 orifice plate, 4 ℃ are spent the night.Control wells is wrapped quilt with 5 μ g/ml bovine serum albumin (BSA), and every hole 100 μ l get rid of the influence of non-specific binding.
(2) sucking-off next day coating buffer adds the 1%BSA sealing, every hole 100 μ l, and incubated at room 1 hour, phosphate buffer (PBS) is washed twice.
(3) to contain 1%BSA, 1mM CaCl
2, 1mM MgCl
2, 1mM MnCl
2RPMI1640 serum-free medium suspension M21 human melanoma cell, every hole adds 8 * 10
4Cell, the experimental group adding is subjected to the reagent thing, and the blank group adds solvent PBS in contrast, 37 ℃ of 5%CO
2Hatched in the incubator 1 hour.
(4) sucking-off culture medium, every hole add 200 μ l PBS, wash gently three times, to remove not adherent cell.
(5) discard PBS, every hole adds 100 μ l, 10% glutaraldehyde and fixes 30 minutes.
(6) thoroughly clean with deionized water wash to glutaraldehyde, put 37 ℃ of baking oven finish-dryings.
(7) the crystal violet pair cell of adding 0.1% dyes jolting 30 minutes.
(8) use distilled water wash, rinse well, put 37 ℃ of baking oven finish-dryings to unnecessary crystal violet.
(9) crystal violet of the acetic acid pair cell of adding 10% absorption is extracted.
Measure on microplate reader after (10) 1 hours, wavelength is 595nm.
Experimental result:
N-(3, the 4-Dichlorobenzene base) biguanide shows the tumor cell of integrin alpha v beta 3 high expressed and the adhesion experimental result of ligands specific vitronectin, N-(3, the 4-Dichlorobenzene base) biguanide can obviously suppress the adhesion of tumor cell and vitronectin, and being the dose-dependence (see figure 2), the IC50 value is 10.61 ± 1.04 μ g/ml.Control compound does not almost have inhibitory action to the adhesion of tumor cell.
Pharmacological evaluation two cell injury healing experiment
Principle:
The wound healing experiment is used for studying the migration of number of different types cell, and in the research through being commonly used in metastasis and angiogenesis medicament.After the cell of monolayer culture was damaged or strikes off, the cell of damage zone will increase the secretion of somatomedin, propagation by cell and the migration damage of healing.The wound healing of cell monolayer can be observed in 3-24 hour.When carrying out the wound healing experiment, mark a band with rifle head or syringe needle on the cell of monolayer growth usually, cell outstanding and migration to injury region in damage back is estimated the result in the distance of different time migration by the record cell.
Method:
Experiment is divided into the every hole of 24 orifice plates and does three markings longitudinally at the bottom of plate.Get the good human melanoma cell of growth conditions, adjusting cell concentration is 2 * 10
4/ ml is inoculated in 24 orifice plates, and every hole 500 μ l are cultured to 90% cell and converge, and are replaced by serum-free medium, spends the night in 37 ℃ of 5%CO2 incubators, uses diameter to be about standardized horizontal scratch of lancet point of 2.5mm.With aseptic PBS washing three times, remove the cell that comes off in the scratching process.Add N-(3, the 4-Dichlorobenzene base) biguanide of 2.5,5,10 μ g/ml, and establish the matched group that does not add medicine, establish three parallel holes for every group.The migration distance of scratch and markings infall cell after the following record of the inverted phase contrast microscope different time points.
Experimental result:
As shown in Figure 3, line damage is after 8 hours, and cellular control unit has moved 0.31mm, and under the N-(3, the 4-Dichlorobenzene base) of 2.5,5,10 μ g/ml biguanide effect, and 0.21,0.083 and 0mm, the migration suppression ratio is respectively 32.3%, 73.2% and 100%.After 18 hours, cellular control unit has moved 1.19mm, and the experimental group cell that has added 2.5,5,10 μ g/mlN-(3, the 4-Dichlorobenzene base) biguanide has moved 0.72,0.39 and 0.2mm respectively, and the migration suppression ratio is respectively 39.5%, 67.2% and 83.2%.Therefore, this chemical compound not only can obviously suppress tumor cell migration, can also play long-acting inhibitory action.
Pharmacological evaluation three vascular endothelial cell tube chambers form experiment
Principle:
The umbilical vein vascular endothelial cell can be under the effect of VEGF, in the gel rubber system that artificial Matrigel forms, form the blood capillary spline structure: the cell that is cobble sample profile originally, cell space elongates and has blastogenesis shape tubular structure to stretch out and make cell space irregular, often interconnect with tubular structure between adjacent ameboid cell, prolonging in the cyton longitudinal axis or the overhanging tubular structure Chang Kejian has translucent cavity or crack to occur.Research at present thinks that endotheliocyte is similar to its angiogenic process in vivo in these changes of artificial Matrigel, thereby can be used to detect the combined influence of different medicines to endotheliocyte angiogenesis ability.
Method:
The artificial Matrigel of ECM is spread 96 orifice plates into pre-cooling, every hole 60 μ l, 37 ℃ solidified 1 hour.Every hole adds 2 * 10
4Human umbilical vein endothelial cells (HUVEC), the basic fibroblast growth factor (bFGF) that adds 100ng/ml in the positive controls, negative control group adds the bFGF of 100ng/ml and the test-compound of 10 μ g/ml with PBS in contrast in the processed group, establish three parallel holes for every group.Hatch observed result after 6 hours under 37 ℃ of 5%CO2 conditions
Experimental result:
Human umbilical vein endothelial cells is under the inducing of bFGF, can on artificial Matrigel, form the tube chamber spline structure that is similar to new vessels, see Fig. 4, wherein, Fig. 4 A does not have the inductive endotheliocyte of the factor, B is that the bFGF of 100ng/ml induces down the interconnected tube chamber spline structure that forms, C is for having added 10 μ g/ml N-(3, the 4-Dichlorobenzene base) processed group of biguanide, though also added the somatomedin bFGF of same amount in this group, but because the anti-angiogenic rebirth effect of chemical compound can not form the tube chamber spline structure.
The two staining apoptosis experiments of pharmacological evaluation four Annexin V/PI
Principle:
Tumor cell can promote tumor existence by the adhesion of cell and extracellular matrix, if this adhesive attraction is suppressed, then cell death inducing rapidly is called as " anoikis " (anoikis).Apoptotic cell has anti-metachromia to the dyestuff PI that is used for the cytoactive evaluation, and non-viable non-apoptotic cell then can not.Cell membrane has the DNA of the non-viable non-apoptotic cell of damage by PI to dye the generation red fluorescence, and the apoptotic cell that cell membrane remains intact does not then have red fluorescence and produces.Therefore, apoptotic early stage PI not can dye and do not have the red fluorescence signal.Normal living cells similarly.On the scatterplot of bivariate flow cytometer, left lower quadrant shows living cells, is (FITC
-/ PI
-); Right upper quadrant is non-living cells, and promptly non-viable non-apoptotic cell is (FITC
+/ PI
+); And right lower quadrant is an apoptotic cell, manifests (FITC
+/ PI
-)
Method:
(1) the take the logarithm human melanoma cell of trophophase, adjusting cell concentration is 5 * 10
5/ ml spreads into 6 porocyte culture plates, adds N-(3, the 4-Dichlorobenzene base) biguanide of different 0,5,10 μ g/ml respectively, hatches 24 hours under 37 ℃ of 5%CO2 conditions.
After (2) 24 hours, collecting cell, centrifugal 5 minutes of 4 ℃ of 1000rpm abandon supernatant.
(3) with the dilution proportion binding buffer liquid (binding buffer) of sterilized water by 1: 4
(4) concentration of adjusting cell to be measured with binding buffer is 5 * 10
5～1 * 10
6/ ml. gets the 1ml cell, and centrifugal 5 minutes of 4 ℃ of 1000rpm abandon supernatant.
(5) with 1ml PBS washing 1 time, centrifugal 5 minutes of 1000rpm.
(6) with 0.5ml binding buffer re-suspended cell, get 195 μ l cell suspension, add 5 μ l AnnexinV and 10 μ l PI, lucifuge is hatched 10 ~ 15min under the room temperature
(7) add 300 μ l Binding Buffer, go up machine (flow cytometer) immediately and detect: flow cytometer excitation wavelength 488nm is the passband filter detection FITC fluorescence of 515nm with a wavelength, and another wavelength detects PI greater than the filter of 560nm.
Experimental result:
The result shows, see that with untreated cell Fig. 5 (Fig. 5 A) compares, the N-(3 of 5 μ g/ml (Fig. 5 B) and 10 μ g/ml (Fig. 5 C), the 4-Dichlorobenzene base) biguanide was handled after 24 hours, thereby can both be by suppressing cell adhesion inducing cell " anoikis ", apoptosis rate increases by 27.7% and 44.9% respectively, is dose dependent.
Preliminary study in the pharmacological evaluation five body constituents
Utilize the human melanoma cell of integrating plain high expressed to set up the experimental metastasis model of nude mice, in order to assessing compound antitumor action in vivo.
(1) foundation of the experimental metastasis model of nude mice
The BALB/Cnu/nu nude mouse, in 4～6 ages in week, body weight 18～22 grams available from Nat'l Pharmaceutical ﹠ Biological Products Control Institute's animal center, are raised under the qualified environment of SPF (specific pathogen free) level.Nude mouse is through 150cGy's
137The total irradiation of Cs-gamma-rays, random packet, every group of 3 animals.Use in 12～72h
Number injection needle slowly injects 2 * 10 through the tail vein
6The M21 cell.
(2) anti-tumor in vivo transfer activity experiment
Experiment is divided into negative control group and treatment group, and negative control group gives normal saline in contrast.The biguanide to N-(3, the 4-Dichlorobenzene base) is organized in treatment, is divided into two dosage of height.From inoculating back the 2nd day, administration every day 1 time, totally 20 times.
(3) observation of curative effect
Observe the general situation of nude mice during the administration, body weight of weighing in per two days.Disconnected neck at the 7th weekend is put to death animal in the inoculation back.Separate after weighing and cut the nude mice lungs, use scales/electronic balance weighing, again that it is fixing with BouinShi liquid (saturated picric acid 75ml+40% formaldehyde 25ml+ glacial acetic acid 5ml), lung tissue is yellow behind the 48h, and the neoplasm metastasis kitchen range becomes the white protuberance.Observe and record lung metastasis number and size with anatomic microscope, and press the size fractionation of metastasis.The routine paraffin wax section, HE dyeing, pathological study.The result shows that N-(3, the 4-Dichlorobenzene base) biguanide can obviously suppress lung in vivo and shift nodular formation.The variation of treatment back nude mice body weight can reflect the toxic action of medicine indirectly, the animal of treatment group is compared with not treatment group, not only do not alleviate, on the rise on the contrary, N-(3 is described, the 4-Dichlorobenzene base) biguanide does not have overt toxicity to animal, and can overcome not treatment group owing to shifting losing weight of causing.The PRELIMINARY RESULTS prompting, N-(3, the 4-Dichlorobenzene base) biguanide can be efficiently, the inhibition neoplasm metastasis of low toxicity, because N-(3, the 4-Dichlorobenzene base) biguanide can estimate that to the targeting of integrin alpha V β 3 it also may produce tangible antimetastatic activity to the tumor of other integrin alpha v beta 3 high expressed.
In sum, vivo and vitro experiment by pharmacology can further prove: substituted aryl biguanides derivant of the present invention demonstrates the effect of transfer of obvious suppression tumor cell invasion and angiogenesis, have characteristics efficient, low toxicity simultaneously, therefore be expected to using aspect the multiple malignant tumor medicines such as the Humanmachine tumour that suppresses tumor invasion transfer and angiogenesis and treatment integrin alpha v beta 3 high expressed, ovarian cancer, pulmonary carcinoma, gastric cancer, carcinoma of prostate, glioma.
The present invention is used for the treatment of the pharmaceutical composition of malignant tumor, and it comprises as the substituted aromatic base biguanide compound of active component and one or more pharmaceutically acceptable carriers, excipient or diluent.
At this, contain the formed pharmaceutical composition of exemplary embodiments 7 effective ingredient of the present invention in order to show the practicality of target compound (I), to provide below.
Substituted aromatic base biguanides series compound of the present invention is normally taken with the form of pharmaceutical composition, can oral or non-oral administration, perhaps with the oral or non-oral administration of chemical compound (as tablet, slow releasing preparation, capsule, injection, the solution) safety that forms with pharmaceutically acceptable carrier, excipient and other additive.When oral administration, compositions can be mixed with tablet, sugar-coat agent or capsule.For the preparation combination of oral medication can adopt lactose or starch to do carrier, gelatin, sodium carboxymethyl cellulose, methylcellulose, polyvinylpyrrolidone etc. are suitable bonding agent or become an agent.Can select starch or microcrystalline Cellulose for use as disintegrating agent, often with Pulvis Talci, santocedl, tristerin, calcium stearate or magnesium etc. are as suitable antiadhesives and lubricant.For example, can prepare tablet by the compacting wet granular.Active component and carrier and optionally with a disintegrate additive composition mixture; the aqueous solution of this mixture and binding agent; alcohol or aqueous alcohol solution carry out granulating in suitable device; dried particles adds other disintegrating agent subsequently, and lubricant and antiplastering aid are with this mixture tabletting.
Substituted aromatic base biguanides series compound of the present invention can the injection form administration, though dosage changes according to treatment target, administering mode, symptom and other factor.When parenterai administration, compositions of the present invention is made into ejection preparation.
Chemical compound of the present invention is effective in quite wide dosage range.For example the dosage of taking every day can be in the scope of the about 0.5mg-1200mg of per kilogram of body weight.In adult's treatment, dosage range once or is several times taken preferably at 1mg/kg-50mg/kg.The dosage of the actual chemical compound of taking should be decided according to relevant situation by the doctor, these situations comprise by the condition of therapist, the person's of choosing route of administration, age, body weight, patient are to the individual reaction of medicine, order of severity of patient's symptom or the like, therefore above-mentioned dosage range is not to limit the scope of the invention by any way.
The specific embodiment
In order to explain enforcement of the present invention more fully, provide following example of formulations.These embodiment explain rather than limit the scope of the invention.Preparation can adopt the active component of any one chemical compound among the present invention.
Preparation 1
Every preparation tablets that contains the 10mg active component is as follows:
Consumption/sheet weight concentration (%)
Chemical compound (2) 100mg 10.0
Microcrystalline Cellulose 35mg 35.0
Starch 45mg 45.0
Polyvinylpyrrolidone 4mg 4.0
Carboxymethyl starch sodium salt 4.5mg 4.5
Magnesium stearate 0.5mg 0.5
Pulvis Talci 1mg 1.0
Amount to 100 100.0
With active component, starch and cellulose sieve, and fully mix, polyvinylpyrrolidonesolution solution is mixed with above-mentioned powder, sieve, make wet granular in 50-60 ℃ of drying, with the carboxymethyl starch sodium salt, magnesium stearate and Pulvis Talci sieve in advance, join tabletting in the above-mentioned granule then.
Preparation 2
The preparation of injection
Chemical compound (5) 200mg
Mannitol 700mg
PEG3000 10mg
Distilled water 100ml
Making pH value is that 7.0-7.5 filtration filter liquor concentration is 3 mg/ml, by 2 milliliters of packing of every peace bottle, promptly gets injection after the lyophilization.
Preparation 3
Every capsule contains the capsular of 100mg active component and is prepared as follows:
Consumption/capsule weight concentration (%)
Chemical compound (7) 100mg 30.0
Polyoxyethylene dehydration Pyrusussuriensis 0.05mg 0.02
The sugar alcohol monoleate
Starch 250mg 69.98
Amount to 350.05mg 100.00
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100133080A CN1846694B (en) | 2005-04-12 | 2005-04-12 | Application of substituted aryl biguanide compounds and pharmaceutical compositions containing them in the preparation of anticancer drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100133080A CN1846694B (en) | 2005-04-12 | 2005-04-12 | Application of substituted aryl biguanide compounds and pharmaceutical compositions containing them in the preparation of anticancer drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1846694A true CN1846694A (en) | 2006-10-18 |
| CN1846694B CN1846694B (en) | 2012-02-01 |
Family
ID=37076578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100133080A Expired - Fee Related CN1846694B (en) | 2005-04-12 | 2005-04-12 | Application of substituted aryl biguanide compounds and pharmaceutical compositions containing them in the preparation of anticancer drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1846694B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011147528A1 (en) * | 2010-05-26 | 2011-12-01 | Merck Patent Gmbh | Biguanide compounds and its use for treating cancer |
| JP2014524424A (en) * | 2011-08-08 | 2014-09-22 | ハノル バイオファーマ カンパニーリミテッド | N1-cyclic amine-N5-substituted phenyl biguanide derivative, process for its preparation and pharmaceutical composition containing it |
| CN106748941A (en) * | 2016-11-28 | 2017-05-31 | 武汉福山生物科技有限公司 | Selenium-containing compound and application thereof |
| CN106986791A (en) * | 2017-05-11 | 2017-07-28 | 杜剑平 | It is a kind of to treat medical compounds of tumour and its preparation method and application |
| US10626085B2 (en) | 2014-11-20 | 2020-04-21 | Immunomet Therapeutics Inc. | Biguanide compound and use thereof |
| CN111138660A (en) * | 2019-12-20 | 2020-05-12 | 浙江大学 | A kind of preparation method of fluorinated polyhexamethylene biguanide |
| CN112574071A (en) * | 2019-09-30 | 2021-03-30 | 复旦大学 | Amphiphilic metformin derivative with biguanide group connected with fatty carbon chain and pharmaceutical application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1154841A (en) * | 1996-01-19 | 1997-07-23 | 张志宏 | Releasing tablet of insoral hydrochloride |
-
2005
- 2005-04-12 CN CN2005100133080A patent/CN1846694B/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011147528A1 (en) * | 2010-05-26 | 2011-12-01 | Merck Patent Gmbh | Biguanide compounds and its use for treating cancer |
| JP2014524424A (en) * | 2011-08-08 | 2014-09-22 | ハノル バイオファーマ カンパニーリミテッド | N1-cyclic amine-N5-substituted phenyl biguanide derivative, process for its preparation and pharmaceutical composition containing it |
| US9540325B2 (en) | 2011-08-08 | 2017-01-10 | ImmunoMet Therapeutics, Inc. | N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| US10626085B2 (en) | 2014-11-20 | 2020-04-21 | Immunomet Therapeutics Inc. | Biguanide compound and use thereof |
| US11572341B2 (en) | 2014-11-20 | 2023-02-07 | Immunomet Therapeutics Inc. | Biguanide compound and use thereof |
| CN106748941A (en) * | 2016-11-28 | 2017-05-31 | 武汉福山生物科技有限公司 | Selenium-containing compound and application thereof |
| CN106986791A (en) * | 2017-05-11 | 2017-07-28 | 杜剑平 | It is a kind of to treat medical compounds of tumour and its preparation method and application |
| CN112574071A (en) * | 2019-09-30 | 2021-03-30 | 复旦大学 | Amphiphilic metformin derivative with biguanide group connected with fatty carbon chain and pharmaceutical application thereof |
| CN111138660A (en) * | 2019-12-20 | 2020-05-12 | 浙江大学 | A kind of preparation method of fluorinated polyhexamethylene biguanide |
| CN111138660B (en) * | 2019-12-20 | 2020-12-08 | 浙江大学 | A kind of preparation method of fluorinated polyhexamethylene biguanide |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1846694B (en) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6555568B1 (en) | Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids | |
| CN1255062A (en) | Use of quinazoline compounds for the treatment of polycystic kidney disease | |
| US6521659B2 (en) | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | |
| JP6883917B2 (en) | CXCR-2 inhibitor for treating crystalline joint disorders | |
| CN109761899A (en) | Quinoline, its pharmaceutically acceptable salt or its solvate, its application, drug and pharmaceutical composition | |
| TW201605450A (en) | Combination of Mdm2 inhibitor and BRAF inhibitor and their use | |
| CN106794180A (en) | Conjoint therapy | |
| JP5759000B2 (en) | Application of diindolylmethane and its precursors and their derivatives in the manufacture of drugs for the treatment of liver diseases | |
| CN1846694A (en) | Application of substituted aryl biguanide compounds and pharmaceutical compositions containing them in the preparation of anticancer drugs | |
| CN101060885A (en) | Treating depressive disorders with carbonic anhydrase activators | |
| RU2549441C2 (en) | Methods and pharmaceutical compositions for treating down syndrome | |
| CN1173705C (en) | Cmbination therapy to treat hepatitis b virus | |
| JP7033317B2 (en) | Use of cataract prophylaxis, therapeutic agents, and HAT inhibitors to make them | |
| US10450295B2 (en) | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | |
| CN105732583A (en) | Targeted compound for treating glioblastoma multiforme | |
| CN102451177A (en) | Application of butylphthalide or derivatives thereof in preparation of angiogenesis promoting drugs | |
| CN114907337B (en) | Covalent inhibitors targeting CDK4 or CDK6 and uses thereof | |
| CN105669666A (en) | Small molecule compound YF-452 and application thereof in preparation of anti-angiogenesis drugs | |
| JP6672173B2 (en) | Treatment of advanced non-alcoholic steatohepatitis | |
| KR102057441B1 (en) | Pharmaceutical composition for preventing or treating immunocyte migration-related diseases comprising benzo[d]thiazole derivatives | |
| CN101336909A (en) | Application of butein in the preparation of drugs for inhibiting angiogenesis | |
| EA007004B1 (en) | Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell prolifiration and inducers of cell differentiation | |
| US20050143453A1 (en) | Selective preventing and therapeutic agents for progressive lesion after organic damage | |
| CN104292126B (en) | Naphthalene derivatives and the application on medicine thereof | |
| CN114099497B (en) | Application of 4-cinnamyl-3-hydroxy pyrrolidone compound in preparation of diabetes treatment drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120201 Termination date: 20140412 |